Handelsavisen
prelaunch
Companies Healthcare 300937.SZ
30
300937.SZ Shenzhen Stock Exchange Pharmaceuticals

Sichuan Hz-yeg Medical Co Ltd

¥24,76
Open in Charts → Attach watcher ⌖
CNY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
ROE
Net margin
Debt / equity
0,41
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

SICHUAN HZ-YEG MEDICAL Co Ltd operates in the pharmaceuticals industry, focusing on the development, production, and sale of medical products and services.

Business. SICHUAN HZ-YEG MEDICAL Co Ltd (300937.SZ) is a healthcare company operating in the pharmaceuticals industry, primarily engaged in pharmaceuticals and medical research. The firm generates revenue through the sale of products and is headquartered in Sichuan, China. It is listed on the Shenzhen Stock Exchange under the ticker symbol 300937.SZ. Specific details regarding operating segments or geographic revenue breakdowns are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
not yet wired
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 300937.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 300937.SZ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    SICHUAN HZ-YEG MEDICAL Co Ltd (300937.SZ) is a healthcare company operating in the pharmaceuticals industry, primarily engaged in pharmaceuticals and medical research. The firm generates revenue through the sale of products and is headquartered in Sichuan, China. It is listed on the Shenzhen Stock Exchange under the ticker symbol 300937.SZ. Specific details regarding operating segments or geographic revenue breakdowns are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    SICHUAN HZ-YEG MEDICAL Co Ltd has a debt-to-equity ratio of 0.41, indicating a relatively conservative capital structure with a moderate level of leverage. The company's liquidity is assessed as medium, and its net cash position is negative after subtracting total debt, suggesting potential short-term liquidity constraints.

    In terms of profitability, the company reported a revenue of 4.45 billion CNY, but its operating cash flow is negative at -13.23 million CNY, indicating that the company is not generating sufficient cash from operations to cover its expenses. The capital expenditure of -7.57 million CNY suggests that the company is investing in its operations, but the negative cash flow from operations may limit its ability to fund these investments internally.

    The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no detailed breakdown of geographic exposure provided in the available data. This lack of diversification may expose the company to higher risks if demand in its primary market declines.

    The company's growth trajectory is not clearly defined in the available data, as there are no specific numeric deltas or revenue history provided for the current or next fiscal year. However, the company's capital expenditure suggests a commitment to maintaining or expanding its operations, which could support future growth.

    The company's risk assessment indicates a medium level of liquidity risk and a low level of dilution risk. The negative net cash position after subtracting total debt is a key flag, suggesting that the company may need to seek external financing to meet its obligations. There are no specific dilution sources or adjustments applied in the valuation data, indicating that the company has not recently issued new shares or has significant dilution potential.

    Recent events and filings do not provide specific details on the company's operations or financial performance beyond the financial snapshot. The company's financial statements and disclosures do not mention any significant recent events that would impact its operations or financial position.

    Key takeaways
    • SICHUAN HZ-YEG MEDICAL Co Ltd has a conservative capital structure with a debt-to-equity ratio of 0.41.
    • The company's operating cash flow is negative, indicating potential liquidity constraints.
    • The company's revenue is concentrated in a single business segment, with no detailed geographic exposure provided.
    • The company's growth trajectory is not clearly defined, and there are no specific numeric deltas provided for the current or next fiscal year.
    • The company's risk assessment indicates a medium level of liquidity risk and a low level of dilution risk.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥24,76
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    Net cash
    -¥338.2M
    Current ratio
    Debt / equity
    0.4
    ROA
    ROE
    Cash conversion
    CapEx / revenue
    -0.2%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Capex / Rev-0,2 %Above P75
    D/E0,41Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    Source documents
    • SICHUAN HZ-YEG MEDICAL Co Ltd Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    300937.SZCanonical
    Shenzhen Stock Exchange · CNY

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage